Core C: Radiosensitization Core

项目总结/摘要（放射增敏核心） 该SPORE内的放射增敏核心将提供专业知识、仪器和 为每个项目的辐射评估研究活动提供技术服务 治疗剂的致敏作用。这些服务包括照射培养细胞和动物模型， 制定皮下和原位肿瘤适形照射的治疗计划， 使用成像的治疗反应，目的是优化联合治疗的剂量和时间表 以理性和机制驱动的方式。核心具有三个正电压单位，一个SARRP（小 动物辐射研究平台），该平台允许生物发光和CT引导的辐射输送， 动物以及激光显微照射仪器来研究单细胞中的DNA修复。另夕h 放射增敏核心将是SPORE研究人员访问内部研究资源的中心渠道。 Rogel癌症中心，包括药代动力学共享资源和临床前成像， 计算分析共享资源。巴尔特博士，将监督与图像引导放射有关的活动 治疗和适形治疗计划。Rehemtulla博士将指导小鼠癌症模型的研究， 成像，为每个项目特定的治疗范例提供定量和机制的见解。 博士Leopold将监督与临床前优化剂量和试验药物时间表相关的研究， 通知每个项目中计划的临床试验设计的方式。放射增敏核心还将 与SPORE中的其他核心无缝合作，生物统计学和计算生物学核心， 转化病理学核心，以确保临床前研究的规划和执行 科学严谨，并与每个项目的目标相一致。的整合 每个研究项目和核心的放射增敏核心至关重要，将提供孢子 研究者进行研究的能力，积极影响患者的管理， 放射治疗

PROJECT SUMMARY/ABSTRACT (Radiosensitization Core) The Radiosensitization Core within this SPORE will provide specialized expertise, instrumentation and technical services to each of the Projects for their research activities related to evaluation of radiation sensitization of therapeutic agents. These services include irradiation of cultured cells and animal models, development of treatment plans for conformal irradiation of subcutaneous and orthotopic tumors, evaluation of therapeutic response using imaging with the goal of optimizing dose and schedule of the combination therapies in a rational and mechanism driven manner. The Core features three orthovoltage units, a SARRP (Small Animal Radiation Research Platform) which permits bioluminescence and CT-guided delivery of radiation to animals as well a laser microirradiation instrument to study DNA repair in single cells. Additionally, the Radiosensitization Core will be a central conduit for SPORE investigators to access research resources within the Rogel Cancer Center, including the Pharmacokinetics Shared Resource and the Preclinical Imaging and Computational Analysis Shared Resource. Dr. Balter, will oversee activities related to image-guided radiation therapy and conformal treatment planning. Dr. Rehemtulla, will guide studies on mouse models of cancer and imaging to provide quantitative and mechanistic insights for each of the project-specific therapeutic paradigms. Dr. Leopold will oversee research related to preclinical optimization of dosing and schedule for test agents in a manner that informs design of the planned clinical trials in each project. The Radiosensitization Core will also work seamlessly with the other Cores within the SPORE, the Biostatistics and Computational Biology Core and the Translational Pathology Core, to ensure that the planning and execution of pre-clinical studies is conducted with scientific rigor and consistent with the goals of each of the projects. The integration of the Radiosensitization core with each of the research Projects and the Cores is critical and will provide SPORE investigators the ability to conduct studies that positively impact the management of patients undergoing radiation therapy.